Sorrento Therapeutics (SRNE) PT Lowered to $18 at Dawson James, Based on Latest Covistix Study
Tweet Send to a Friend
Dawson James analyst Jason Kolbert lowered the price target on Sorrento Therapeutics (NASDAQ: SRNE) to $18.00 (from $19.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
